PhD. Dr. MD. Herjan Coelingh Bennink,
Herjan Coelingh Bennink (HCB), MD, PhD, founded Pantarhei Bioscience (PRB) in 2001 for the development of new drugs for Women’s Health (WH) applications, such as the natural fetal steroid Estetrol (E4) and a new oral contraceptive preserving sexual function (Androgen Restored Contraception). In 2014 HCB founded Pantarhei Oncology (PRO) for the development of drugs for reproductive tract cancers such as an immunological method for the treatment of ovarian cancer (Zona Pellucida antigen immunisation) in collaboration with HRA in Paris, France. In 2015 Mithra in Liège, Belgium acquired the rights for the development of E4 from PRB for all WH applications such as oral contraception and HRT, whereas PRO will develop E4 for breast and prostate cancer treatment.